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The immune system is tightly controlled by co-
stimulatory and co-inhibitory ligands and re-
ceptors. These  molecules  provide  not  only  a 
second signal for T cell activation but also a bal-
anced network of positive and negative signals 
to maximize immune responses against infec-
tion while limiting immunity to self.
The  best  characterized  co-stimulatory  li-
gands are B7.1 and B7.2, which belong to the 
Ig  superfamily  and  are  expressed  on  profes-
sional APCs  and  whose  receptors  are  CD28 
and CTLA-4 (Greenwald et al., 2005). CD28 is 
expressed by naive and activated T cells and is 
critical for optimal T cell activation. In contrast, 
CTLA-4 is induced upon T cell activation and 
inhibits T cell activation by binding to B7.1/
B7.2, impairing CD28-mediated co-stimulation. 
B7.1 and B7.2 KO mice are impaired in adap-
tive immune response (Borriello et al., 1997), 
whereas CTLA-4 KO mice cannot adequately 
control  inflammation  and  develop  systemic   
autoimmune  diseases  (Tivol  et  al.,  1995;   
Waterhouse et al., 1995; Chambers et al., 1997).
The B7 family ligands have expanded to   
include co-stimulatory B7-H2 (inducible T cell 
co-stimulator  [ICOS]  ligand)  and  B7-H3,  as 
well as co-inhibitory B7-H1 (PD-L1), B7-DC 
(PD-L2), B7-H4 (B7S1 or B7x), and B7-H6 
(Greenwald et al., 2005; Brandt et al., 2009). 
Accordingly, additional CD28 family receptors 
have been identified. ICOS is expressed on ac-
tivated T cells and binds to B7-H2 (Yoshinaga 
et  al.,  1999).  ICOS  is  a  positive  coregulator, 
which is important for T cell activation, differen-
tiation, and function (Yoshinaga et al., 1999; Dong 
et al., 2001). In contrast, PD-1 (programmed 
death 1) negatively regulates T cell responses. 
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The immunoglobulin (Ig) superfamily consists of many critical immune regulators, including 
the B7 family ligands and receptors. In this study, we identify a novel and structurally 
distinct Ig superfamily inhibitory ligand, whose extracellular domain bears homology to the 
B7 family ligand PD-L1. This molecule is designated V-domain Ig suppressor of T cell acti-
vation (VISTA). VISTA is primarily expressed on hematopoietic cells, and VISTA expression is 
highly regulated on myeloid antigen-presenting cells (APCs) and T cells. A soluble VISTA-Ig 
fusion protein or VISTA expression on APCs inhibits T cell proliferation and cytokine pro-
duction in vitro. A VISTA-specific monoclonal antibody interferes with VISTA-induced 
suppression of T cell responses by VISTA-expressing APCs in vitro. Furthermore, anti-VISTA 
treatment exacerbates the development of the T cell–mediated autoimmune disease experi-
mental autoimmune encephalomyelitis in mice. Finally, VISTA overexpression on tumor cells 
interferes with protective antitumor immunity in vivo in mice. These findings show that 
VISTA, a novel immunoregulatory molecule, has functional activities that are nonredundant 
with other Ig superfamily members and may play a role in the development of autoimmu-
nity and immune surveillance in cancer.
© 2011 Wang et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1.  Sequence and structural analysis of VISTA. (A) The primary amino acid sequence of mouse VISTA with the Ig-V domain, the stalk segment, JEM VOL. 208, March 14, 2011 
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diseases such as autoimmunity and cancer (Keir et al., 2008; 
Zou and Chen, 2008). In the context of extending our under-
standings of immune regulation, this study identifies a novel 
immune regulatory ligand, referred to as V-domain Ig sup-
pressor of T cell activation (VISTA). We demonstrate that the 
extracellular Ig domain of VISTA shares significant sequence 
homology with the B7 family ligands PD-L1 and PD-L2, al-
beit with unique structural features that distinguish it from 
the B7 family members. Together with its distinctive expres-
sion pattern and functional impact on T cell activation, it is 
concluded that VISTA represents a novel immune regulatory 
ligand within the Ig superfamily.
RESULTS
Cloning and sequence and structural analysis of VISTA
Affymetrix  analysis  of  activated  versus  resting  mouse 
CD25+ CD4+ natural Treg cells (nTreg cells) revealed the ex-
pression of a gene product (RIKEN cDNA 4632428N05 or 
4632428N05Rik) with unknown function but with sequence 
homology to the Ig superfamily. A 930-bp gene product was 
cloned from the mouse CD4+ T cell cDNA library, which 
matched the predicted size and sequence. Silico sequence and 
structural analysis predicts a type I transmembrane protein of 
309 aa upon maturation. Its extracellular domain contains a 
single extracellular Ig-V domain of 136 aa, which is linked to 
a 23-aa stalk region, a 21-residue transmembrane segment, 
and a 97-aa cytoplasmic domain (Fig. 1 A). The cytoplasmic 
tail of 4632428N05Rik does not contain any signaling do-
mains. Based on the structural feature of the Ig-V domain and 
its immune-suppressive function that is shown in this study, 
this molecule is named VISTA.
A BLAST (Altschul et al., 1990) sequence search with the 
VISTA Ig-V domain identified PD-L1 of the B7 family as the 
closest evolutionarily related protein with a borderline signif-
icant e-value score of 104 and with a sequence identity of 
24%. These relationships were confirmed by computationally 
threading the sequence of the VISTA Ig-V domain through 
all known structures. This threading exercise indicated with a 
high but not certain confidence (P < 0.001) that the structure 
of  VISTA is most similar to the Ig-V domains of PD-L1 (Pro-
tein Data Bank accession no. 3BIS; Lin et al., 2008), PD-L2 
(Protein Data Bank accession no. 3BOV; Lázár-Molnár et al., 
2008), and MOG (myelin oligodendrocyte glycoprotein; Pro-
tein Data Bank accession no. 1PKO; Breithaupt et al., 2003), 
PD-1 KO mice developed lupus-like autoimmune disease 
or autoimmune dilated cardiomyopathy (Nishimura et al., 
1999, 2001). The autoimmunity most likely results from the 
loss of signaling by both ligands PD-L1 and PD-L2. Recently, 
CD80 was identified as a second receptor for PD-L1 that trans-
duces inhibitory signals into T cells (Butte et al., 2007).
The two inhibitory B7 family ligands, PD-L1 and PD-L2, 
have  distinct  expression  patterns.  PD-L2  is  inducibly  ex-
pressed on DCs and macrophages, whereas PD-L1 is broadly 
expressed on both hematopoietic cells and nonhematopoietic 
cell types (Okazaki and Honjo, 2006; Keir et al., 2008). Con-
sistent with the immune-suppressive role of PD-1 receptor, a 
study using PD-L1/ and PD-L2/ mice has shown that 
both ligands have overlapping roles in inhibiting T cell prolif-
eration and cytokine production (Keir et al., 2006). PD-L1 
deficiency enhances disease progression in both the nonobese 
diabetic model of autoimmune diabetes and the mouse model 
of  multiple  sclerosis  (experimental  autoimmune  encephalo-
myelitis [EAE]; Ansari et al., 2003; Salama et al., 2003; Latchman   
et al., 2004). PD-L1/ T cells produce elevated levels of the 
proinflammatory cytokines in both disease models. In addi-
tion, BM chimera experiments have demonstrated that the 
tissue expression of PD-L1 (i.e., within pancreas) uniquely 
contributes to its capacity of regionally controlling inflamma-
tion (Keir et al., 2006, 2007; Grabie et al., 2007). PD-L1 is also 
highly  expressed  on  placental  syncytiotrophoblasts,  which 
critically control the maternal immune responses to alloge-
neic fetus (Guleria et al., 2005).
Consistent with its immune-suppressive role, PD-L1 po-
tently suppresses antitumor immune responses and helps tu-
mors evade immune surveillance. PD-L1 can induce apoptosis 
of infiltrating cytotoxic CD8+ T cells, which express a high 
level of PD-1 (Dong et al., 2002; Dong and Chen, 2003). 
Studies have shown that blocking the PD-L1–PD-1 signaling 
pathway, in conjunction with other immune therapies, pre-
vents tumor progression by enhancing antitumor CTL activ-
ity and cytokine production (Iwai et al., 2002; Blank et al., 
2004, 2005; Geng et al., 2006). More recently, we have shown 
that PD-L1 expression on DCs promotes the induction of 
adaptive Foxp3+CD4+ regulatory T cells (aTreg cells), and PD-
L1 is a potent inducer of aTreg cells within the tumor micro-
environment (Wang et al., 2008).
Recent advances in targeting B7 family regulatory mole-
cules have shown great promise in treating immune-related 
and the transmembrane region highlighted in blue, green, and red, respectively. Cysteines in the ectodomain region are indicated by underlining. (B) A 
comparative protein structure model of mouse VISTA using PD-L1 as the template (Protein Data Bank accession no. 3BIS). The five cysteine residues in the 
Ig-V domain are illustrated as orange sticks. Based on this model, the VISTA Ig-V domain has the canonical disulfide bond between the B and F strands, as 
well as three additional cysteines, some of which can potentially form inter- and intramolecular disulfide bonds. An additional invariant cysteine is pres-
ent in the stalk region following the G strand (not depicted). The  strands (A–G) are marked as green and blue. The C-D loop is marked by an arrow.  
(C) Multiple sequence alignment of the Ig-V domains of several B7 family members and VISTA. The predicted secondary structure (using arrows, springs, and 
“T”s for strands, helices, and -turns, respectively) is marked above the alignment and is based on the VISTA structural model. (D) Multiple sequence align-
ment of VISTA orthologues. Invariant residues are represented by the red background, and physico-chemically conserved positions are represented by red 
letters. Conserved amino acids are marked by blue boxes. Conservation is calculated on the basis of 36 VISTA orthologous proteins, but only 9 representa-
tives are shown. The canonical cysteine pair (B and F strands) that is conserved in almost all Ig superfamily members is highlighted by red circles, whereas 
cysteines that are specific to VISTA are marked by blue circles. The unique VISTA cysteine pattern is conserved in all orthologues from zebrafish to human.
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but a lower expression level on B cells (Fig. 2 B). This expression 
pattern is also largely consistent with the GNF (Genomics 
Institute of the Novartis Research Foundation) gene array 
database (symbol 4632428N05Rik; Su et al., 2002), as well 
as  the  National  Center  for  Biotechnology  Information 
GEO  (Gene Expression  Omnibus)  database  (accession  no. 
GDS868; Fig. S2).
To study the protein expression, VISTA-specific hamster 
mAbs were produced. The specificity is demonstrated by pos-
itive staining on  VISTA-overexpressing mouse EL4 T cells but 
negative staining on PD-L1–overexpressing EL4 cells (Fig. S3).
Using an -VISTA mAb clone 8D8, VISTA expression 
was analyzed on hematopoietic cells by flow cytometry. 
Foxp3-GFP knockin reporter mice were used to distinguish 
CD4+ nTreg cells (Fontenot et al., 2005). In peripheral lym-
phoid  organs  (spleen  and  LNs),  significant  expression  was 
seen on all CD4+ T cell subsets (see total CD4+ T cells or 
Foxp3 naive T cells and Foxp3+ nTreg cells and memory 
CD4+ T cells), whereas CD8+ T cells expressed a markedly 
lower amount of surface VISTA (Fig. 2 C). In thymus, VISTA 
expression was negative on CD4+CD8+–double positive thy-
mocytes, low on CD4–single positive cells, and detectable on 
CD8–single positive cells. Next, a strong correlation of high 
VISTA expression with CD11b marker was seen for both 
splenic and peritoneal cells, including both F4/80 macro-
phages and myeloid CD11c+ DCs (Fig. 2, D and E). In con-
trast, B cells and NK cells were mostly negative for VISTA 
expression. A small percentage of Gr-1+ granulocytes also ex-
pressed VISTA (Fig. 2 F).
A differential expression pattern was shown on the same 
lineage of cells from different lymphoid organs (Fig. 2 G). For 
CD4+ T cells and CD11bintermediate monocytes, the expression 
level followed the pattern of mesenteric LN > peripheral LN 
and spleen > peritoneal cavity and blood. This pattern was 
less pronounced for CD11bhi cells. These data suggest that 
VISTA expression on certain cell types might be regulated by 
cell maturity and/or tissue microenvironment.
In addition to freshly isolated cells, VISTA expression was 
analyzed on splenic CD4+ T cells, CD11bhi monocytes, and 
CD11c+ DCs upon in vitro culture with and without activa-
tion (Fig. 3). Spleen cells were cultured with medium, with 
-CD3 (for activating T cells), or with IFN- and LPS (for 
activating monocytes and DCs) for 24 h before expression 
analysis of VISTA and other B7 family ligands (e.g., PD-L1, 
PD-L2, B7-H3, and B7-H4). This comparison revealed dis-
tinctive expression patterns between these molecules. VISTA 
expression was quickly lost on all cell types upon in vitro cul-
ture, regardless of the activation status. In contrast, PD-L1 ex-
pression was up-regulated on activated CD4+ T cells or on 
CD11bhi monocytes and CD11c+ DCs after culture in me-
dium alone and further enhanced upon stimulation. The ex-
pression of PD-L2, B7-H3, and B7-H4 was not prominent 
under the culture conditions used. The loss of VISTA expres-
sion in vitro is unique when compared with other B7 family 
ligands but might reflect nonoptimal culture conditions that 
fail to mimic the tissue microenvironment.
as well as CAR (coxsackie and adenovirus receptor; Protein 
Data Bank accession no. 1EAJ; van Raaij et al., 2000) and 
VCBP3, an ancient Ig superfamily member from a primitive 
deuterostome  (Protein  Data  Bank  accession  no.  1XT5; 
Hernández Prada et al., 2006). The first three of these proteins 
belong to the B7-butyrophilin family of co-stimulatory li-
gands, whereas the last two do not. Based on these results, we 
constructed a structural model of mouse  VISTA using PD-L1 
as the template (Fig. 1 B).
A structure-based sequence alignment of VISTA with the 
B7  family  members  PD-L1,  PD-L2,  B7-H3,  and  B7-H4 
highlights several amino acids that are known to be systemati-
cally conserved in all Ig-V domain proteins and are thought 
to be important for the stability of the Ig-V fold (Fig. 1 C). 
Examples include the two cysteines in the B and the F  
strands that form a disulfide bond between the two  sheets, 
which is a hallmark feature of Ig superfamily proteins (Fig. 1 C). 
This multiple sequence alignment also reveals additional se-
quence features that are unique to VISTA. Notably, in addi-
tion to the canonical two cysteines, the VISTA Ig-V domain 
contains three additional cysteine residues that are not present 
in other Ig superfamily members. A multiple sequence align-
ment of  VISTA orthologous proteins from 36 species demon-
strates that all five of these cysteines are invariant (Fig. 1 D). 
In addition, a sixth cysteine, found in the stalk region proxi-
mal to the membrane, is also invariant among all VISTA   
orthologues (Fig. 1, C and D). Other distinctions between 
VISTA and the B7 proteins are the insertion of a long loop 
between the C and D strands (Fig. 1 C) and the fact that 
most B7 proteins have a second Ig domain in their ectodo-
main, which is absent in VISTA. In addition, we performed a 
comprehensive BLAST comparison of all 559 currently known 
human secreted proteins and the ectodomains of human inte-
gral membrane proteins that contain Ig domains. Clustering 
at various confidence limits reveals that VISTA is not strongly 
related to other members of the Ig superfamily (Fig. S1). 
Specifically, at an e-value threshold of 105, nearly all Ig super-
family members cluster together showing little or no discrim-
ination between families (i.e., the B7 family is interspersed 
with numerous other unrelated sequences). At an e-value of 
1010, the B7 family is clearly segregating from the other su-
perfamily members, whereas  VISTA becomes an outlier and is 
classified as a singleton with no direct connections to other 
superfamily members.
Expression experiments of VISTA by RT-PCR analysis  
and flow cytometry
RT-PCR analysis was used to determine the messenger RNA 
expression  pattern  of VISTA  in  mouse  tissues  (Fig.  2 A). 
VISTA is mostly expressed on hematopoietic tissues (spleen, 
thymus, and BM) or tissues with ample infiltration of leuko-
cytes (i.e., lung). Weak expression was also detected in non-
hematopoietic tissues (i.e., heart, kidney, brain, and ovary). 
Analysis of several hematopoietic cell types revealed expres-
sion of VISTA on peritoneal macrophages, splenic CD11b+ 
monocytes, CD11c+ DCs, CD4+ T cells, and CD8+ T cells JEM VOL. 208, March 14, 2011 
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Figure 2.  Tissue expression and hematopoietic cell expression patterns of VISTA. (A and B) RT-PCR of full-length VISTA from mouse tissues  
(A) and from mouse hematopoietic cell types (B). GAPDH was used as a loading control. (C–F) Flow cytometry analysis of VISTA expression on various 
hematopoietic cell types. (C) Total populations of CD4+ and CD8+ T cells from thymus, LN, and spleen or subsets of CD4+ T cells (i.e., Foxp3+ nTreg cells and 
naive and memory CD4+ T cells) from spleen. (D and E) CD11b+ monocytes and CD11c+ DC subsets from spleen and peritoneal cavity. (F) Splenic B cells, NK 
cells, and granulocytes. (G) VISTA expression on hematopoietic cells from different tissue sites, including mesenteric LN, peripheral LN, spleen, blood, and 
peritoneal cavity. Representative data from at least three independent experiments are shown.582 A new Ig superfamily inhibitory ligand | Wang et al.
VISTA-Ig contained the extracellular domain of  VISTA fused 
to the human IgG1 Fc region. When immobilized on the   
microplate, VISTA-Ig but not control-Ig suppressed the pro-
liferation of bulk purified CD4+ and CD8+ T cells in response 
to -CD3 stimulation (Fig. 5, A and B). The VISTA-Ig did 
not affect the absorption of anti-CD3 antibody to the plastic 
wells, as determined by ELISA (unpublished data), thus ex-
cluding the possibility of nonspecific inhibitory effects. The 
inhibitory  effect  of  PD-L1–Ig  and VISTA-Ig  was  directly 
compared (Fig. S5). When titrated amounts of Ig fusion pro-
teins were absorbed to the microplates together with -CD3 
to stimulate CD4+ T cells, VISTA-Ig showed potent inhibi-
tory efficacy similar to the PD-L1–Ig fusion protein. PD-1 
KO CD4+ T cells were also suppressed (Fig. 5 C), indicating 
that PD-1 is not the receptor for VISTA.
Because bulk purified CD4+  T cells contain various subsets, the 
impact of VISTA-Ig on sorted naive (CD25CD44lowCD62Lhi) 
and memory (CD25CD44hiCD62Llow) CD4+ T cell subsets 
was evaluated (Fig. S6). VISTA suppressed the proliferation of 
both subsets, albeit with less efficacy on the memory cells.
To further understand the mechanism of VISTA-mediated 
suppression, the expression of early TCR activation mark-
ers and apoptosis were measured after T cell activation. 
To address how  VISTA expression might be regulated in vivo, 
CD4 TCR transgenic mice DO11.10 were immunized with the 
cognate antigen chicken OVA emulsified in CFA. At 24 h after 
immunization, cells from the draining LN were analyzed for 
VISTA expression (Fig. 4 A). Immunization with antigen (CFA/
OVA)  but  not  the  adjuvant  alone  drastically  increased  the 
CD11b+ VISTA+ myeloid cell population, which contained a 
mixed population of F4/80+ macrophages and CD11c+ DCs. 
Further comparison with PD-L1 and PD-L2 revealed that even 
though  PD-L1  had  the  highest  constitutive  expression  level, 
VISTA was the most highly up-regulated during such an inflam-
matory  immune  response  (Fig.  4  B).  Collectively,  these  data 
strongly suggest that the expression of VISTA on myeloid APCs 
is tightly regulated by the immune system, which might contrib-
ute to its role in controlling immune responses. In contrast to its 
increased expression on APCs,  VISTA expression was diminished 
on activated DO11.10 CD4+ T cells at a later time point upon 
immunization (i.e., at 48 h but not at 24 h; Fig. S4).
Functional impact of VISTA signaling on CD4+ and CD8+  
T cell responses in vitro
A VISTA Ig fusion protein (VISTA-Ig) was produced to ex-
amine the regulatory roles of VISTA on CD4+ T cell responses. 
Figure 3.  Comparison of expression of VISTA and other B7 family ligands on in vitro cultured spleen cells. Expression of VISTA and other B7 
family ligands (i.e., PD-L1, PD-L2, B7-H3, and B7-H4) on hematopoietic cell types, including CD4+ T cells, CD11bhi monocytes, and CD11c+ DCs, was com-
pared. Cells were either freshly isolated or in vitro cultured for 24 h, with and without activation. CD4+ T cells were activated with 5 µg/ml plate-bound 
-CD3, and CD11bhi monocytes and CD11c+ DCs were activated with 20 ng/ml IFN- and 200 ng/ml LPS. Representative results from three independent 
experiments are shown.JEM VOL. 208, March 14, 2011 
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T cell responses by suppressing early 
TCR activation and arresting cell di-
vision but with minimum direct im-
pact on apoptosis. This mechanism of 
suppression is similar to that of B7-H4 
(Sica et al., 2003).
A two-step assay was developed to 
determine  whether  VISTA-Ig  can 
suppress preactivated CD4 T cells and 
how persistent its suppressive effect is. 
The suppressive effect of  VISTA-Ig fu-
sion protein persisted after its removal 
at 24 h after activation (Fig. 5 D, ii).   
In  addition,  both  naive  and  preacti-
vated CD4+ T cells were suppressed by 
VISTA-Ig (Fig. 5 D, i, iii, and iv).
Next, the effect of VISTA-Ig on 
CD4+ T cell cytokine production was 
analyzed.  VISTA-Ig  suppressed  the 
production  of  Th1  cytokines  IL-2 
and IFN- from bulk purified CD4+  
T cell culture (Fig. 6, A and B). The 
impact of VISTA was further tested 
on separate naive (CD25CD44lowCD62Lhi) and memory 
(CD25CD44hiCD62Llow) CD4+ T cell populations. Mem-
ory CD4+ T cells were the major source for cytokine produc-
tion  within  the  CD4+ T  cell  compartment,  and VISTA 
suppressed this production (Fig. 6, C and D). IFN- produc-
tion from CD8+ T cells was also inhibited by VISTA-Ig 
(Fig. 6 E). This inhibitory effect of VISTA on cytokine produc-
tion by CD4+ and CD8+ T cells is consistent with the hypoth-
esis that VISTA is an inhibitory ligand that down-regulates   
T cell–mediated immune responses.
Further experiments were designed to determine the fac-
tors that are able to overcome the inhibitory effect of VISTA. 
Given that VISTA suppressed IL-2 production and IL-2 is 
critical for T cell survival and proliferation, we hypothesized 
that IL-2 might circumvent the inhibitory activity of VISTA.   
Consistent with the negative effect on cell proliferation, there 
was a global suppression on the expression of the early activa-
tion markers CD69, CD44, and CD62L (Fig. S7 A). In con-
trast, VISTA-Ig did not induce apoptosis. Less apoptosis (as 
determined by the percentage of annexin V+ 7AAD cells) 
was seen in the presence of VISTA-Ig than the control-Ig at 
both early (24 h) and later (48 h) stages of TCR activation 
(Fig. S7 B). For example, at 24 h, of the total ungated popula-
tion, 27% of cells were apoptotic in the presence of VISTA- 
Ig,  but  39%  of  cells  were  apoptotic  in  the  presence  of 
control-Ig. Similarly, of the cells within the live cell R1 gate, 
72.6% cells became apoptotic in the presence of control-Ig, 
whereas only 43.5% cells were apoptotic in the presence of 
VISTA-Ig. Similar results were seen at the 48-h time point. 
Therefore, it appears that VISTA negatively regulates CD4+  
Figure 4.  Comparison of in vivo  
expression patterns of VISTA and B7  
family ligands PD-L1 and PD-L2 during 
immunization. DO11.10 TCR transgenic mice 
were immunized with 200 µg chicken OVA 
emulsified in CFA or CFA alone on the flank. 
Draining LN (DLN) and nondraining LN cells 
were collected after 24 h and analyzed by 
flow cytometry for the expression of VISTA, 
PD-L1, and PD-L2. (A) Representative VISTA 
expression profile on CD11b+ monocytes at 24 h 
after immunization. (B) Expression of VISTA,  
PD-L1, and PD-L2 on CD11bhi monocytes, 
CD11c+ DCs, and CD4+ T cells was analyzed  
at 24 h after immunization. Shown are repre-
sentative results from at least four indepen-
dent experiments.584 A new Ig superfamily inhibitory ligand | Wang et al.
In addition to the  VISTA-Ig fusion 
protein, it was necessary to confirm 
that  VISTA expressed on APCs can sup-
press antigen-specific T cell activation 
during cognate interactions between 
APCs and T cells. We have used two 
independent  cell  systems  to  address 
this  question.  First, VISTA-RFP  or 
RFP control protein was overexpressed 
via retroviral transduction in a B cell 
line  A20. The  correct  cells  surface   
localization of VISTA-RFP fusion pro-
tein was confirmed by fluorescence 
microscopy (unpublished data). To stim-
ulate T  cell  response, A20-VISTA  or 
A20-RFP  cells  were  incubated  to-
gether with DO11.10 CD4+ T cells in 
the presence of antigenic OVA pep-
tide. As shown in Fig. 8 (A and B), 
A20-VISTA induced less proliferation 
of DO11.10 cells than A20-RFP cells. 
This suppressive effect is more pronounced at lower peptide 
concentrations, which is consistent with the notion that a 
stronger stimulatory signal would overcome the suppressive 
impact of VISTA.
Second, the inhibitory effect of full-length  VISTA on nat-
ural APCs was confirmed. In vitro cultured BM-derived DCs 
(BMDCs) did not express high levels of VISTA (Fig. S8). 
VISTA-RFP or RFP was expressed in BMDCs by retroviral 
transduction during the 10-d culture period. Transduced cells 
were sorted to homogeneity based on RFP expression. The 
expression level of VISTA on transduced DCs was estimated 
As shown in Fig. 7 A, exogenous IL-2 but not IL-15, IL-7, or 
IL-23 partially reversed the suppressive effect of VISTA-Ig on 
cell proliferation. The incomplete rescue by high levels of IL-2 
indicates that  VISTA signaling targets broader T cell activation 
pathways than simply IL-2 production. In contrast, potent co-
stimulatory signals provided by -CD28 agonistic antibody 
completely reversed VISTA-Ig–mediated suppression (Fig. 7 B), 
whereas intermediate levels of co-stimulation continued to be 
suppressed by VISTA signaling (Fig. 7 C). In this regard, VISTA 
shares this feature with other suppressive B7 family ligands such 
as PD-L1 and B7-H4 (Carter et al., 2002; Sica et al., 2003).
Figure 5.  Immobilized VISTA-Ig fusion 
protein inhibited CD4+ and CD8+ T cell 
proliferation. CFSE-labeled CD4+ and CD8+ T 
cells were stimulated by plate-bound -CD3 
together with co-absorbed VISTA-Ig or con-
trol-Ig protein at the indicated ratios. (A) Rep-
resentative CFSE dilution profiles. (B) The 
percentage of CFSE-low cells was quantified 
and shown as mean ± SEM. (C) As in A, but 
using CD4+ T cells from PD-1–deficient mice. 
(D) Wild-type CD4+ T cells were activated in 
the presence of VISTA-Ig or control-Ig for 72 (i) 
or 24 h (ii–iv). 24-h preactivated cells were 
harvested and restimulated under specified 
conditions for another 48 h. (ii) Preactivation 
with VISTA-Ig and restimulation with -CD3. 
(iii) Preactivation with -CD3 and restimula-
tion with control-Ig or VISTA-Ig. (iv) Preacti-
vation with control-Ig or VISTA-Ig and 
restimulation with the same Ig protein. Cell 
proliferation was analyzed at the end of the 
72-h culture. Duplicated wells were analyzed 
for all conditions. Shown are representative 
results from at least four experiments.JEM VOL. 208, March 14, 2011 
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control virus. Because MCA105 tumor is immunogenic and 
can be readily controlled in hosts preimmunized with irradi-
ated MCA105 cells (Mackey et al., 1997), we examined the 
effect of tumor VISTA expression on such protective immu-
nity. As shown in Fig. 9 A, VISTA-expressing MCA105 grew 
vigorously in vaccinated hosts, whereas the control tumors 
failed to thrive. To confirm that there is no intrinsic differ-
ence in tumor growth rate in the absence of T cell–mediated 
antitumor immunity, tumors were inoculated in vaccinated 
animals in which both CD4+ and CD8+ T cells were de-
pleted using mAbs. As shown in Fig. 9 B, upon T cell deple-
tion, both MCA105RFP and MCA105VISTA tumors grew 
at an equivalent rate and much more rapidly than non– 
T-depleted hosts. Together, these data indicate that VISTA ex-
pression  on  tumor  cells  can  interfere  with  the  protective 
antitumor immunity in the host.
by staining with -VISTA mAb and found to be similar to 
the  level  on  freshly  isolated  peritoneal  macrophages,  thus 
within the physiological expression range (Fig. S8). Sorted 
BMDCs were then used to stimulate OVA-specific transgenic 
CD4+ T cells (OT-II) in the presence of OVA peptide. The 
expression of VISTA on BMDCs suppressed the cognate 
CD4+ T cell proliferation (Fig. 8 C). This result is consistent 
with data (Fig. 5) using VISTA-Ig fusion protein or VISTA-
expressing A20  cells,  suggesting  that VISTA  expressed  on 
APCs can suppress T cell–mediated immune responses.
To validate the impact of VISTA expression in vivo, we 
examined whether VISTA overexpression on tumor cells could 
impair the antitumor immune response. MCA105 (methyl-
cholanthrene 105) fibrosarcoma does not express VISTA (un-
published data). Two MCA105 tumor lines were established 
by retroviral transduction with either VISTA-RFP or RFP 
Figure 6.  VISTA-Ig inhibited cytokine production by CD4+ and CD8+ T cells. (A and B) Bulk purified CD4+ T cells were stimulated with plate-bound 
-CD3 and VISTA-Ig or control-Ig at the stated ratios. Culture supernatants were collected after 24 and 48 h. Levels of IL-2 and IFN- were analyzed by 
ELISA. (C and D) CD4+ T cells were sorted into naive (CD25CD44lowCD62Lhi) and memory (CD25CD44hiCD62Llow) cell populations. Cells were stimulated 
with plate-bound -CD3 in the presence of VISTA-Ig or control-Ig at a ratio of 1:2 (2.5 µg/ml -CD3 and 5 µg/ml VISTA-Ig or control-Ig). Culture super-
natants were collected at 48 h, and the level of IL-2 and IFN- was analyzed by ELISA. (E) Bulk purified CD8+ T cells were stimulated with plate-bound  
-CD3 and VISTA-Ig or control-Ig at the indicated ratios. The level of IFN- in the culture supernatant was analyzed by ELISA. For all conditions, supernatant 
from six duplicated wells was pooled for ELISA analysis and shown as means ± SEM. Shown are representative results from at least three experiments.586 A new Ig superfamily inhibitory ligand | Wang et al.
control antibody did not reach 100% disease incidence during 
the experimental duration. The mean disease score was sig-
nificantly higher in the 13F3-treated group than the control 
group  throughout  the  disease  course.  Consistent  with  the 
higher disease score, analysis of the central nervous system at 
the end of disease course confirmed significantly more IL-17A–
producing CD4+ T cell infiltration in the 13F3-treated group 
(unpublished data).
DISCUSSION
This study presents  VISTA as a novel member of the Ig super-
family network, which exerts immunosuppressive activities 
on T cells both in vitro and in vivo and could be an important 
mediator in controlling the development of autoimmunity 
and the immune responses to cancer. The data presented show 
that (a) VISTA is a new member of the Ig superfamily that 
contains an Ig-V domain with distant sequence similarity to 
PD-L1, (b) when produced as an Ig fusion protein or overex-
pressed on artificial APCs, it inhibits both CD4 and CD8+  
T cell proliferation and cytokine production, (c) VISTA ex-
pression on myeloid APCs is inhibitory for T cell responses   
in vitro, (d) overexpression on tumor cells impairs protective   
antitumor immunity in vaccinated mice, and (e) antibody- 
mediated VISTA blockade exacerbates the development of a 
T cell–mediated autoimmune disease, EAE.
Bioinformatics analysis of the VISTA Ig-V domain sug-
gests that the B7-butyrophilin family members PD-L1, PD-
L2, and MOG, as well as the non-B7 family CAR and  VCBP3 
VISTA blockade by a specific mAb enhanced T cell responses 
in vitro and in vivo
A VISTA-specific mAb (13F3) was identified to neutralize 
VISTA-mediated suppression in the A20-DO11.10 assay sys-
tem (Fig. 10 A). To further confirm the impact of 13F3 on   
T cell responses, CD11bhi myeloid APCs were purified from 
naive mice to stimulate OT-II transgenic CD4+ T cells in the 
presence or absence of 13F3 (Fig. 10 B). Consistent with its 
neutralizing effect, 13F3 enhanced T cell proliferation stimu-
lated by CD11bhi myeloid cells, which were shown to ex-
press high levels of VISTA (Fig. 2). A similar effect of 13F3 
could be seen on both CD11bhiCD11c+ myeloid DCs and 
CD11bhiCD11c monocytes (Fig. 10 C).
Next, the impact of VISTA blockade by mAb was exam-
ined in a passive transfer model of EAE, which is a mouse auto-
immune  inflammatory  disease  model  for  human  multiple 
sclerosis  (Stromnes  and  Goverman,  2006a,b).  Encephalito-
genic CD4+ T cells were primed in the donor mice by active 
immunization with proteolipid protein (PLP) peptide and 
adoptively transferred into naive mice. So as to carefully eval-
uate the ability of -VISTA to exacerbate disease, tittered 
numbers of activated encephalitogenic T cells were passively 
transferred into naive hosts treated with -VISTA or control-
Ig, and the development of EAE was monitored. 13F3 was 
found to significantly accelerate disease onset, as well as exac-
erbate disease severity under the suboptimal T cell transfer 
dosage (Fig. 10 D). The 13F3-treated group reached 100% 
disease incidence by day 14, whereas those mice treated with 
Figure 7.  VISTA-Ig–mediated suppression 
could overcome a moderate level of co-
stimulation provided by CD28 but was 
completely reversed by a high level of co-
stimulation, as well as partially rescued by 
exogenous IL-2. (A and B) CFSE-labeled CD4+ 
T cells were activated by 2.5 µg/ml plate-
bound -CD3 together with either VISTA-Ig or 
control-Ig at 1:1 and 1:2 ratios. (A) 40 ng/ml 
soluble mIL-2, mIL-7, mIL-15, or mIL-23 was 
also added as indicated to the cell culture.  
(B) 1 µg/ml -CD28 was immobilized together 
with 2.5 µg/ml -CD3 and Ig proteins at the 
indicated ratios. Cell proliferation was ana-
lyzed at 72 h by examining CFSE division pro-
files. (C and D) To examine the suppressive 
activity of VISTA in the presence of lower 
levels of co-stimulation, the indicated 
amounts of -CD28 were coated together 
with 2.5 µg/ml -CD3 and 10 µg/ml VISTA-Ig 
fusion proteins or control-Ig fusion protein to 
stimulate CFSE-labeled CD4+ T cells. Cell pro-
liferation was analyzed at 72 h. Percentages 
of CFSElow cells were quantified and shown as 
means ± SEM in D. Duplicated wells were 
analyzed in all conditions. Representative 
CFSE profiles from three independent experi-
ments are shown.JEM VOL. 208, March 14, 2011 
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bonds at a dimer interface, and (c) form 
one intramolecular and two intermolec-
ular disulfide bonds. Any of these sce-
narios would represent a novel disulfide 
bonding pattern and would lead to unique 
tertiary and/or quaternary structures rel-
ative to typical Ig superfamily members. 
In addition, a global sequence compari-
son suggests that VISTA is not a member 
of any known functional groups within 
the  Ig  superfamily  (Fig.  S1). Together, 
these observations highlight the unique 
properties of VISTA and underscore the 
need for future studies to define the re-
lationships  between VISTA  sequence, 
structure, and function.
The expression pattern of  VISTA fur-
ther distinguishes VISTA from other B7 
family ligands. This study has contrasted 
mostly with PD-L1 and PD-L2 because 
of  the  higher  sequence  homology  be-
tween these two ligands and VISTA and their similar inhibi-
tory function on T cell activation. The steady-state expression 
of VISTA is largely restricted to hematopoietic cells and most 
highly expressed on both APCs (macrophages and myeloid 
DCs) and CD4+ T lymphocytes. In this context, PD-L1 has 
broad expression on both hematopoietic and nonhematopoi-
etic cells, whereas PD-L2 is restricted on DCs and macro-
phages (Keir et al., 2006, 2008). Although both PD-L1 and 
PD-L2 are up-regulated on APCs upon in vitro culture and 
upon activation (Yamazaki et al., 2002; Liang et al., 2003; Keir 
et al., 2008), VISTA expression on myeloid cells and T cells is 
lost after short-term in vitro culture, regardless of whether 
any stimuli were present (Fig. 3). Such loss might reflect the 
are the closest evolutionary relatives of VISTA (Fig. 1). How-
ever, close examination of primary sequence signatures sug-
gests that all VISTA orthologues share unique and conserved 
sequence motifs and that VISTA possibly represents a struc-
turally and functionally novel member of the Ig superfamily. 
Specifically, the presence of four invariant cysteines that are 
unique to the VISTA ectodomain (three in the Ig-V domain 
and one in the stalk) may contribute to novel structural fea-
tures that impact its function. Given their strict invariance, it 
is plausible that all four VISTA-specific cysteines participate 
in disulfide bonds. This observation suggests several possibili-
ties, including that the four cysteines (a) form two intramo-
lecular disulfide bonds, (b) form four intermolecular disulfide 
Figure 8.  VISTA expressed on APCs sup-
pressed CD4+ T cell proliferation. (A and B) A20 
cells were transduced with retrovirus express-
ing either VISTA-RFP or RFP control molecules 
and sorted to achieve homogenous level of  
expression. To test their ability as APCs, A20-
VISTA or A20-RFP cells were mitomycin C treated 
and mixed with CFSE-labeled DO11.10 TCR trans-
genic CD4+ T cells in the presence of a titrated 
amount of OVA peptide. CFSE dilution in DO11 
cells was analyzed after 72 h. (A) Representative 
CFSE profiles. (B) Percentages of CFSElow cells 
were quantified and shown as mean ± SEM.  
(C) BMDCs were transduced with RFP or VISTA-RFP 
retrovirus during 10-d culture period. Transduced 
and nontransduced DCs were sorted based on 
RFP expression and used to stimulate CFSE- 
labeled OT-II transgenic CD4+ T cells in the pres-
ence of the indicated amount of OVA peptide. 
CFSE dilution was analyzed after 72 h. For all 
experiments, duplicated wells were analyzed in 
all conditions, and representative results from 
three independent experiments are shown.588 A new Ig superfamily inhibitory ligand | Wang et al.
immunization but to a much lesser degree. We speculate that 
the induction of  VISTA+ myeloid APCs constitutes a self-regula-
tory  mechanism  to  curtail  an  ongoing  immune  response. 
Consistent with this hypothesis, a neutralizing VISTA mAb 
enhanced T cell proliferative response in vitro when stimulated 
by VISTA-expressing myeloid APCs (Fig. 10).
In contrast to the expression pattern on myeloid cells, 
VISTA expression is diminished on in vivo activated CD4+  
T cells. This result suggests that VISTA expression on CD4   
T cells in vivo may be regulated by its activation status and cyto-
kine microenvironment during an active immune response. 
Such down-regulation is unique and has not been seen for 
other inhibitory B7 family ligands such as PD-L1, PD-L2, 
and B7-H4. Although the functional significance of VISTA 
expression on CD4+ T cells is currently unknown, the possi-
bility of reverse signaling from T cells to APCs during their 
cognate interaction will be investigated in future studies.
The inhibitory ligand function of VISTA was delineated by 
using the VISTA-Ig fusion protein, APCs expressing VISTA, 
and tumors overexpressing VISTA, as well as the neutralizing 
mAb both in vitro and in vivo. VISTA-overexpressing tumor 
could overcome a potent protective immunity in vaccinated 
hosts. The strong enhancing effect of  VISTA mAb in the EAE 
model further validates the hypothesis that VISTA is an in-
hibitory ligand in vivo. Similar approaches have been used to 
characterize the functions of other B7 family ligands (Sica et al., 
2003; Keir et al., 2008). It is important to note that  VISTA exerts 
its suppressive function by engaging a different receptor than 
PD-1 (Fig. 5). The fact that blockade of the VISTA pathway 
exacerbates EAE confirms that its function is not redundant with 
PD-L1 or PD-L2. On the contrary, we speculate that VISTA 
controls immune response in a manner that is reflected by its 
unique structural features, expression pattern, and dynamics. 
Identification of its unknown receptor will further shed light 
on the mechanisms of VISTA-mediated suppression.
In summary, this study has identified VISTA as a novel 
immune-suppressive ligand. Expression of VISTA on APCs 
suppresses T cell responses by engaging its yet to be identified 
counter-receptor on T cells during cognate interactions between 
T cells and APCs.  VISTA blockade enhanced T cell–mediated 
immunity in an autoimmune disease model, suggesting its 
unique and nonredundant role in controlling autoimmunity 
when compared with other inhibitory B7 family ligands such 
as PD-L1 and PD-L2. Its highly regulated expression pattern 
at early stages of immune activation might also indicate a 
feedback control pathway to down-regulate T cell immunity 
and attenuate inflammatory responses. In this regard, thera-
peutic intervention of the VISTA inhibitory pathway repre-
sents a novel approach to modulate T cell–mediated immunity 
for treating diseases such as viral infection and cancer.
MATERIALS AND METHODS
Mice. C57BL/6 mice, OT-II CD4 transgenic mice, and SJL/J mice were 
purchased from the Jackson Laboratory. FoxP3-GFP reporter mice were as 
previously described (Fontenot et al., 2005) and were provided by A. Rudensky 
(University of Washington School of Medicine, Seattle, WA). PD-1 KO mice 
necessary role of lymphoid tissue microenvironment to main-
tain or regulate VISTA expression in vivo. Consistent with 
this hypothesis, even at steady-state, VISTA is differentially ex-
pressed at different tissue sites (i.e., higher at mesenteric LN than 
peripheral lymphoid tissues and lowest in blood). We speculate 
that such different expression levels might reflect the differen-
tial suppressive function of VISTA at particular tissue sites.
VISTA expression in vivo is highly regulated during ac-
tive immune response. Immunization with adjuvant plus an-
tigen (OVA/CFA) but not adjuvant alone (CFA) in TCR 
transgenic mice induced a population of VISTAhi myeloid 
APCs within the draining LN (Fig. 4). The need for antigen 
suggests that VISTA up-regulation on APCs might be a result 
of T cell activation. Compared with VISTA, PD-L1 and PD-L2 
were also up-regulated on myeloid APCs in response to   
Figure 9.  VISTA overexpression on tumor cells overcomes protec-
tive antitumor immunity. MCA105 tumor cells overexpressing VISTA or 
RFP control protein were generated by retroviral transduction and sorted 
to homogeneity. To generate protective immunity, naive mice were vac-
cinated with irradiated MCA105 tumor cells subcutaneously on the left 
flank. (A) Vaccinated mice were challenged 14 d later with live 
MCA105VISTA or MCA105RFP tumor cells subcutaneously on the right 
flank. Tumor growth was monitored every 2 d. Tumor size is shown as 
mean ± SEM. Shown are representative results from three independent 
repeats. (B) Vaccinated mice were either untreated or depleted of both 
CD4+ and CD8+ T cells by mAbs before live tumor challenge. Tumor size 
was monitored as in A and shown as mean ± SEM. Shown are representa-
tive results from two independent repeats. For all experiments, ratios 
indicate the number of tumor-bearing mice among total number of mice 
per group. The statistical differences (p-values) were assessed with an 
unpaired Mann-Whitney test.JEM VOL. 208, March 14, 2011 
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kit (QIAGEN). cDNA was generated using an 
iScript cDNA synthesis kit (Bio-Rad Laborato-
ries).  Full-length  VISTA  was  amplified  and 
cloned into the ECORI–XhoI site of a retrovi-
ral vector pMSCV-IRES-GFP (Zhang and Ren, 
1998), in which the IRES-GFP fragment was 
replaced by RFP, thus resulting in a fusion pro-
tein of VISTA fused to the N terminus of RFP. 
Helper  free  retroviruses  were  generated  in 
HEK293T cells by transient transfection of the VISTA-RFP retroviral vector 
together with an ecotrophic packaging vector pCL-Eco (Imgenex Corp.). 
Retroviral transduction of mouse T cell line EL4 cells or BMDCs was per-
formed by spin infection at 2,000 rpm at room temperature for 45 min in the 
presence of 8 µg/ml polybrene (Sigma-Aldrich).
Bioinformatics analysis of  VISTA. Proteins that are evolutionarily related 
to the  VISTA Ig-V sequence were identified by the BLAST algorithm (Altschul 
et al., 1990). The most suitable structural templates from the Protein Data 
Bank (Berman et al., 2000) were identified with the mGenTHREADER 
algorithm (Lobley et al., 2009). PD-L1 (Protein Data Bank accession no. 
3BIS), one of the top scoring hits, was selected as the template for compara-
tive protein structure modeling. The structural model of VISTA was con-
structed  with  the  MMM  server  using  the  optimal  combination  of  two 
alignment methods, MUSCLE and HHalign (Rai and Fiser, 2006; Rai et al., 
2006). 36 VISTA orthologous proteins were collected from the ENSEMBL 
database (Flicek et al., 2008). Structure and sequence alignments were calculated 
with DALI (Holm and Park, 2000) and Clustalw (Larkin et al., 2007), respectively, 
were provided by T. Honjo (Kyoto University, Kyoto, Japan; Nishimura et al., 
1999, 2001). All animals were maintained in a pathogen-free facility at 
Dartmouth Medical School. All animal protocols were approved by the 
Institutional Animal Care and Use Committee of Dartmouth College.
Antibodies, cell lines, and reagents. Antibodies -CD3 (2C11), -CD28 
(PV-1), -CD4 (GK1.5), -CD8 (53-6.7), -CD11b (M1/70), -F4/80 (BM8), 
-CD11c (N418), -NK1.1 (PK136), -Gr1 (RB6-8C5), –PD-L1 (MIN5), 
–PD-L2 (TY25), –B7-H3 (M3.2D7), and –B7-H4 (188) were purchased 
from eBioscience. LPS (Sigma-Aldrich), recombinant mouse IFN- (Pepro-
Tech), human IL-2 (PeproTech), and soluble PD-L1–Ig fusion protein (R&D 
Systems) were used at the indicated concentrations. CFA and chicken OVA 
were purchased from Sigma-Aldrich. The B cell lymphoma cell line A20 
(BALB/c origin) was obtained from the American Type Culture Collection.
Molecular cloning of VISTA, retrovirus production, and retroviral 
transduction of cells. Full-length VISTA was cloned from purified mouse 
CD4+ T cells. Total RNA was isolated from CD4+ T cells using an RNAmini 
Figure 10.  VISTA blockade using a spe-
cific mAb enhanced CD4+ T cell response 
in vitro and in vivo. (A) An mAb clone 13F3 
neutralized VISTA-mediated suppression in 
vitro. A20-RFP and A20-VISTA cells were used 
to stimulate CFSE-labeled DO11.10 CD4+ T 
cells in the presence of cognate OVA peptide. 
20 µg/ml VISTA-specific mAb 13F3 or control-
Ig was added as indicated. CFSE dilution was 
analyzed after 72 h, and percentages of  
CFSElow cells are shown as mean ± SEM. Dupli-
cated wells were analyzed for all conditions. 
(B and C) Total CD11bhi myeloid cells (B) or 
CD11bhiCD11c monocytes (C) and 
CD11bhiCD11c+ myeloid DCs (C) sorted from 
naive splenocytes were irradiated and used to 
stimulate CFSE-labeled OT-II transgenic CD4+ 
T cells in the presence of OVA peptide. Cell 
proliferation was measured by incorporation 
of tritiated thymidine during the last 8 h of a 
72-h culture period and shown as mean ± 
SEM. Triplicate wells were analyzed in all con-
ditions. (D) Mean clinical scores and disease 
incidence of mice (n = 8 per group) that re-
ceived suboptimal dosage of activated en-
cephalitogenic CD4+ T cells (1.5 million). 
Recipient mice were treated with 400 µg 13F3 
or control-Ig every 3 d, and disease course 
was monitored every day. Disease scores are 
shown as means ± SEM and are the represen-
tative results from three independent experi-
ments. The statistical differences (p-values) 
were assessed with an unpaired Mann- 
Whitney test.590 A new Ig superfamily inhibitory ligand | Wang et al.
with 1.25 µg/ml (ratio 2:1), 2.5 µg/ml (ratio 1:1), 5 µg/ml (ratio 1:2), or 
10 µg/ml (ratio 1:4) VISTA-Ig or control-Ig protein in PBS at 4°C over-
night. Wells  were  washed  three  times  with  PBS  before  adding  CD4+  
T cells. Replicate cultures were in complete RPMI 1640 medium supple-
mented with 10% FBS, 10 mM Hepes, 50 µM -ME, and penicillin/
streptomycin/l-glutamine. When indicated, either 100 U/ml human IL-2 
(PeproTech) or a titrated amount of -CD28 (clone PV-1; Bio X Cell) was 
coated together with -CD3 to rescue the inhibitory effects of VISTA-Ig. 
Cultures were analyzed on day 3 for CFSE profiles or according to a time 
course as indicated.
Culture of BMDCs, retroviral transduction, and stimulation of trans-
genic CD4+ T cells. BMDCs were generated as described previously (Lutz 
et al., 1999; Son et al., 2002), with some modifications. In brief, on day 0, BM 
cells were isolated from tibia and femur by flushing with a 27-gauge needle. 
After red blood cell lysis, 1–2 × 106 BM cells were resuspended in 1 ml com-
plete RPMI 1640 medium containing 20 ng/ml GM-CSF (PeproTech). 
Cells were infected with RFP or VISTA-RFP retrovirus in the presence of   
8 µg/ml Polybrene (Sigma-Aldrich). Infection was performed by spinning 
the plate at 2,000 rpm for 45 min at room temperature. Cells were then cul-
tured for another 2 h before fresh medium was added. Similar infection pro-
cedure was repeated on days 1, 3, and 5. Loosely adherent cells (90% were 
CD11c+) were collected on day 10, and CD11c+RFP+–double positive cells 
were sorted and used to stimulate OT-II transgenic CD4+ T cells. For OT-II 
T cell proliferation assays, 100,000 CFSE-labeled OT-II CD4+ T cells were 
cultured  in  96-well  round-bottom  plates  with  30,000  sorted  RFP+  or 
VISTA-RFP+ BMDCs, with a titrated amount of synthetic OVA323–339 pep-
tide (AnaSpec). Proliferation of OT-II T cells was analyzed at 72 h by exam-
ining CFSE profiles.
Tumor experiment. Parent MCA105 tumor cells were retrovirally trans-
duced with VISTA-RFP or RFP control and sorted to homogeneity based 
on RFP expression. For tumor vaccination, naive C57BL/6 mice were im-
munized with 1,000,000 irradiated MCA105 (10,000 rad) cells that were 
inoculated subcutaneously into the left flank. On day 14, vaccinated mice 
were challenged with live MCA105 tumor cells that were inoculated subcu-
taneously into the right flank. Tumor growth was monitored every 2 d. Mice 
were euthanized when tumor size reached 150 mm2. For T cell depletion, 
vaccinated mice were pretreated intraperitoneally (250 µg) with mAb spe-
cific for CD4+ T cells (clone GK1.5) and CD8+ T cells (clone 53.6.72) 2 d 
before live tumor cell challenge, and the treatment was repeated every 3–4 d 
until the end of the experiment. Mice were euthanized when tumor size 
reached 160 mm2.
Passive induction of EAE and characterization of central nervous 
system–infiltrating CD4+ T cells. For passive transfer EAE, female SJL 
mice (6 wk old) were immunized subcutaneously with 200 µl of emulsion 
containing 400 µg Mycobacterium tuberculosis H37Ra and 100 µg PLP peptide. 
Draining LN cells were harvested on day 10 for in vitro stimulation. Red 
blood cells were lysed. Single cell suspensions (10,000,000 per microliter) 
were cultured in complete IMDM medium with 10% FBS, 50 µM 2-ME,   
1 mM glutamine, 1% penicillin/streptavidin, 1 mM nonessential amino acids, 
20 ng/ml IL-23, 10 ng/ml IL-6, 10 ng/ml IL-1, 20 µg/ml anti–IFN-, and 
20 µg/ml PLP peptide. On day 4, cells were harvested, and live CD4 T cells 
were  purified  using  CD4  magnetic  beads  (Miltenyi  Biotec).  1,500,000–
2,000,000 purified live CD4 T cells were adoptively transferred into naive 
SJL mice to induce EAE. Mice were treated with either nonspecific hamster 
control-Ig or 400 µg VISTA-specific mAb every 3 d. Disease was scored as 
the following: 0, no disease; 1, hind limb weakness or loss of tail tone; 2, flac-
cid tail and hind limb paresis; 2.5, one hind limb paralysis; 3, both hind limb 
paralysis; 4, front limb weakness; 5, moribund. Mice were euthanized at a 
score of 4.
Graphs and statistical analysis. All graphs and statistical analysis were 
generated using Prism.
and were presented using the ESPript 2.2 server (Gouet et al., 1999). The BLAST 
pairwise comparison network was constructed as described previously (Atkinson 
et al., 2009) and analyzed using Cytoscape (Shannon et al., 2003).
Production of VISTA-Ig fusion protein. The extracellular domain of 
VISTA (aa 32–190) was amplified and cloned into the SpeI–BamHI sites of 
the parental vector CDM7B (Hollenbaugh et al., 1995). This vector contains 
the mutant form of constant and hinge regions of human IgG1, which has 
much reduced binding to Fc receptors. The resulting vector CDM7B-VISTA 
was cotransfected with a dihydrofolate reductase expression vector pSV-dhfr 
(McIvor and Simonsen, 1990) into the Chinese hamster ovary (dhfr) cell 
line (#CRL-9096; American Type Culture Collection). Stable Chinese 
hamster ovary cell clones that express VISTA-Ig were selected in medium 
MEM-  without  nucleotides  (Invitrogen).  Further  amplification  with 
0.5–1 µM methotrexate (M9929; Sigma-Aldrich) yielded clones express-
ing high levels of soluble VISTA-Ig fusion protein. The fusion protein was 
further purified from culture supernatant using standard protein G column 
affinity chromatography.
Generation of VISTA mAbs. Armenian hamsters were immunized with 
EL4 cells overexpressing VISTA-RFP and then boosted with VISTA-Ig fu-
sion protein emulsified in CFA. 4 wk after the boost, hamsters were boosted 
again with soluble VISTA-Ig fusion protein. 4 d after the last boost, hamster 
spleen cells were harvested and fused to the myeloma cell line SP2/0-Ag14 
(#CRL-1581; American Type Culture Collection) using standard hybridoma 
fusion  techniques  (Shulman  et  al.,  1978).  Hybridoma  clones  that  secret 
VISTA-specific antibodies were selected after limiting dilution and screened 
by both ELISA and flow cytometry methods.
RNA and RT-PCR. Total RNA from various mouse tissue samples or pu-
rified hematopoietic cell types were collected by using TRIZOL (Invitrogen) 
according to the company’s instructions. cDNAs were prepared by using the 
iScript cDNA synthesis kit (Bio-Rad Laboratories). Equal amounts of tissue 
cDNAs (10 ng) were used for RT-PCR reactions to amplify full-length 
VISTA. PCR products were viewed after running through a 1% agarose gel.
Flow cytometry and analysis. Flow cytometry analysis was performed on 
FACScan using CellQuest software (BD). Data analysis was performed using 
FlowJo software (Tree Star, Inc.). To quantify cell proliferation, the histogram 
profile of CFSE divisions was analyzed, and the percentage of proliferative 
CFSElow cells was graphed using Prism 4 (GraphPad Software, Inc.).
Cell preparation. Total CD4+ T cells were isolated from naive mice using a 
total CD4+ T cell isolation kit (Miltenyi Biotec). When indicated, enriched 
CD4+ T cells were flow sorted into naive (CD44lowCD25CD62Lhi) and 
memory (CD44hiCD25CD62Llow) populations. For in vitro proliferation 
assays, CD4+ T cells were labeled with 5 µM CFSE (Invitrogen) for 10 min 
at 37°C and washed twice before being stimulated.
For A20 assay, A20-RFP or A20–PD-XL cells (20,000) were pretreated 
with 100 µg/ml mitomycin C (1 h) and then incubated with CFSE-labeled 
DO11.10 CD4+ T cells (100,000) in the presence of OVA peptide. Control-
Ig or 13F3 mAb was added as indicated. Cell proliferation was analyzed at   
72 h by CFSE dilution. For sorting CD11bhi myeloid APCs, CD11b+ mono-
cytes were enriched from naive splenocytes using CD11b magnetic beads 
(Miltenyi Biotec). Total CD11bhi myeloid APCs, or CD11bhiCD11c mono-
cytes and CD11bhiCD11c+ myeloid DCs were sorted, irradiated (2,500 rad), 
and used to stimulate OT-II transgenic CD4+ T cells in the presence of OVA 
peptide. Control-Ig or 13F3 mAb was added as indicated. Cell proliferation 
was measured by tritium incorporation during the last 8 h of a 72-h assay.
In vitro plate-bound T cell activation assay. Purified CD4+ T cells 
(100,000 cells per well) were cultured in 96-well flat-bottom plates in the 
presence of anti-CD3 (clone 2C11) and either VISTA-Ig or control-Ig at 
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